Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment
about
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the ChallengesEvaluation and consequences of heterogeneity in the circulating tumor cell compartmentNotes for developing a molecular test for the full characterization of circulating tumor cellsDetection of Circulating Tumor Cells in Non-Small Cell Lung CancerCurrent Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerMicrofluidic enrichment for the single cell analysis of circulating tumor cells.Recent advances in the biology of human circulating tumour cells and metastasisLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancerCirculating tumor cells in early stage lung adenocarcinoma: a case series report and literature reviewCancer gene panel analysis of cultured circulating tumor cells and primary tumor tissue from patients with breast cancer.Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation.Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cellsThe potential for liquid biopsies in the precision medical treatment of breast cancer.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Technological advances in precision medicine and drug development.Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Advances in clinical next-generation sequencing: target enrichment and sequencing technologies.Circulating Tumor Cells: Back to the FutureLiquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.Liquid Biopsy in Non-Small Cell Lung Cancer.The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineMolecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Biology and clinical significance of circulating tumor cell subpopulations in lung cancerBiophysical technologies for understanding circulating tumor cell biology and metastasis.Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Blood-based tumor biomarkers in lung cancer for detection and treatment.
P2860
Q26744100-664C95BC-9825-4908-8989-AF0FCD51E78BQ26765357-CD2B815F-30F2-4DDC-9E61-D8F5E5130CA5Q26778913-2C7553C2-2995-44CE-BE35-07B2951D34E9Q26781088-88F24F71-FDAF-4627-A315-1B717BE12702Q26781333-0A453488-A6F0-4F54-8AB1-4ED840B425FFQ26801357-9EF9B20B-409B-42ED-B608-50E107BFC14FQ27340255-0F035AFB-89D3-4C93-BB3F-0BCF017884C6Q28070120-A5CAB05B-D419-4124-AC9A-87DE25CE8644Q28076191-4FF7F614-472B-4564-AB95-69995B29BC65Q28077340-013E6798-029D-41E4-92D1-98B924A27FD9Q28082499-7FB726AB-D709-44C3-9C95-ED54C5234307Q33618596-0946F3D5-B4BB-4829-95D7-CF219305D8DAQ33751043-6C5CBC5F-3177-4EAD-9268-A61A622A8DACQ34550417-1454553D-2AEE-4693-85D3-22F0B4FCF8F9Q35159562-41360693-82FA-4627-B9B0-F27127FA3E04Q35842078-F80918AE-006A-43D3-8D07-03D44635ADD6Q36643142-4E4188B1-A4CD-430D-80A7-E175E3ACFBA4Q36746316-19ADDE2B-FFAF-452F-9C28-337B40AE82DFQ36849660-2077E42C-197E-4B1D-8F03-F99887EB8E75Q37051546-5388255E-19F5-48E2-AE9D-02A2F32EFFDEQ37244501-FEC08F59-7861-4510-8584-331A0067C9FFQ37468081-641DDE3B-0585-4F04-A0A6-1E36F291D59DQ38408223-A61AD1A9-8A51-4EA6-9D86-E7D107AA8B3FQ38513661-C36AA567-01C7-4E98-8F71-0F76FC75EE70Q38672934-C8F3FC25-97EC-4597-9C33-0EB2EC976EA4Q38765748-7D230EE4-EBC6-46D0-A7EC-377B99A9850CQ38770935-224F5791-E6E3-45F8-A21D-7116374FB142Q39076207-9E74FA22-4421-430D-89B9-7CD777F6D83CQ39097813-5578B435-6767-4BA0-BCF6-F6F161B15CF0Q39114552-341914F8-F038-4898-AE12-EA61F6FAA9C5Q39835396-632CF0C7-82BD-444D-B202-48F42781D5D8Q41605016-38AB0039-F7BF-42A8-8C4C-F1DBD7CC6E5EQ41605032-11D56406-5593-47BE-929F-7B6B5146C762Q41605039-8D2E8FA4-B23A-4343-9D54-A86939758A65Q41605055-97C7AE9A-A7FB-4C07-A086-0EAB3CAA5048Q41976096-3E265F5C-FA3C-4A96-AFE1-6A66568D4C23Q45891469-DC382028-B782-413E-B656-6667B9450753Q47104064-486CBC5F-642A-42F5-87F6-0566DA926A3FQ47110464-004550D7-8E4A-488B-9DCF-A136BF9F9AA6Q47126156-2BBF1D56-6F6E-45E7-8B11-2011FA607C9E
P2860
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@ast
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@en
type
label
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@ast
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@en
prefLabel
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@ast
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@en
P2093
P2860
P1433
P1476
Assessment of EGFR mutations i ...... me liquid biopsy for treatment
@en
P2093
Alba Ariela Brandes
Antonio Chella
Antonio Marchetti
Fiamma Buttitta
Franco Cuccurullo
Giampaolo Filice
Irene Centi
Lara Felicioni
Lucio Crinò
Maela Del Grammastro
P2860
P304
P356
10.1371/JOURNAL.PONE.0103883
P407
P577
2014-08-19T00:00:00Z